{"hands_on_practices": [{"introduction": "A critical first step in designing a meaningful PDX study is to establish a dosing regimen in mice that is pharmacologically equivalent to the human clinical dose. Simply adjusting for body weight is insufficient due to differences in metabolic rates between species. This practice will guide you through the principles of allometric scaling, a fundamental pharmacokinetic method used to convert drug doses between species to achieve equivalent systemic exposure, ensuring your preclinical model accurately reflects the clinical context [@problem_id:5039628].", "problem": "You are designing a dosing regimen for an efficacy study using patient-derived xenograft (PDX) models, where human tumor fragments are implanted into immunodeficient mice to preserve clinical tumor heterogeneity and drug response. To translate a clinically used human dose to a mouse-equivalent regimen that targets comparable systemic exposure, you adopt the following foundational pharmacokinetic assumptions: linear pharmacokinetics, identical route of administration with complete bioavailability across species, and an allometric relationship for systemic clearance such that $CL = k\\,W^{\\beta}$, where $CL$ is systemic clearance, $W$ is body weight, $k$ is a species-independent proportionality constant, and $\\beta$ is the allometric exponent. The pharmacologically relevant exposure metric is the area under the concentration-time curve (AUC), with $AUC \\propto \\frac{\\text{Dose}}{CL}$. The administered dose is expressed on a per kilogram basis, so that the absolute dose is $\\text{Dose} = d\\,W$, where $d$ has units $\\mathrm{mg/kg}$.\n\nStarting only from these fundamentals, derive the interspecies mg/kg scaling relation of the form $d_{\\mathrm{mouse}} = d_{\\mathrm{human}}\\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta}$, expressing the exponent $\\theta$ in terms of the clearance exponent $\\beta$. Then compute the mouse mg/kg dose that yields matched exposure to a human regimen with $d_{\\mathrm{human}} = 2.5$ $\\mathrm{mg/kg}$, taking $W_{\\mathrm{human}} = 70$ $\\mathrm{kg}$, $W_{\\mathrm{mouse}} = 0.020$ $\\mathrm{kg}$, and $\\beta = 0.75$.\n\nRound your final numerical answer to four significant figures and express it in $\\mathrm{mg/kg}$. Provide only the numerical value in your final boxed answer; do not include units inside the box.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the established principles of pharmacokinetic allometric scaling, is well-posed with a complete and consistent set of givens, and is expressed in objective, formal language. There are no violations of fundamental principles, contradictions, or ambiguities. We may therefore proceed with the derivation and calculation.\n\nThe central objective is to determine a dosing regimen for a mouse that achieves the same systemic drug exposure, measured by the area under the concentration-time curve ($AUC$), as a known regimen in a human. The problem states that for equivalent exposure, we must have:\n$$\nAUC_{\\mathrm{mouse}} = AUC_{\\mathrm{human}}\n$$\nThe problem provides a proportionality for $AUC$:\n$$\nAUC \\propto \\frac{\\text{Dose}}{CL}\n$$\nwhere `Dose` is the absolute amount of drug administered and $CL$ is the systemic clearance. Since the proportionality constant is independent of species, the condition for matched exposure becomes an equality:\n$$\n\\frac{\\text{Dose}_{\\mathrm{mouse}}}{CL_{\\mathrm{mouse}}} = \\frac{\\text{Dose}_{\\mathrm{human}}}{CL_{\\mathrm{human}}}\n$$\nWe are given two further constitutive relations. First, the absolute dose is defined in terms of a dose per unit body weight, $d$, and the body weight, $W$:\n$$\n\\text{Dose} = d \\cdot W\n$$\nSecond, the systemic clearance, $CL$, is related to body weight, $W$, through an allometric scaling law:\n$$\nCL = k\\,W^{\\beta}\n$$\nHere, $k$ is a species-independent proportionality constant and $\\beta$ is the allometric exponent.\n\nWe can now substitute these two relations into the exposure equality equation. For the mouse and human, respectively, we have:\n$$\n\\frac{d_{\\mathrm{mouse}} \\cdot W_{\\mathrm{mouse}}}{k\\,(W_{\\mathrm{mouse}})^{\\beta}} = \\frac{d_{\\mathrm{human}} \\cdot W_{\\mathrm{human}}}{k\\,(W_{\\mathrm{human}})^{\\beta}}\n$$\nThe species-independent constant $k$ cancels from both sides of the equation:\n$$\n\\frac{d_{\\mathrm{mouse}} \\cdot W_{\\mathrm{mouse}}}{(W_{\\mathrm{mouse}})^{\\beta}} = \\frac{d_{\\mathrm{human}} \\cdot W_{\\mathrm{human}}}{(W_{\\mathrm{human}})^{\\beta}}\n$$\nUsing the property of exponents $\\frac{x^a}{x^b} = x^{a-b}$, we simplify both sides:\n$$\nd_{\\mathrm{mouse}} \\cdot (W_{\\mathrm{mouse}})^{1-\\beta} = d_{\\mathrm{human}} \\cdot (W_{\\mathrm{human}})^{1-\\beta}\n$$\nOur goal is to find an expression for $d_{\\mathrm{mouse}}$ in terms of $d_{\\mathrm{human}}$. We rearrange the equation to solve for $d_{\\mathrm{mouse}}$:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\cdot \\frac{(W_{\\mathrm{human}})^{1-\\beta}}{(W_{\\mathrm{mouse}})^{1-\\beta}}\n$$\nThis can be written more compactly as:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{human}}}{W_{\\mathrm{mouse}}}\\right)^{1-\\beta}\n$$\nThe problem requests the scaling relation in the form $d_{\\mathrm{mouse}} = d_{\\mathrm{human}}\\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta}$. To match this form, we must invert the fraction inside the parentheses, which is equivalent to negating the exponent:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left( \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{-1} \\right)^{1-\\beta} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{-(1-\\beta)}\n$$\nSimplifying the exponent, we get:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\beta - 1}\n$$\nBy comparing this derived expression with the requested form, we can identify the exponent $\\theta$:\n$$\n\\theta = \\beta - 1\n$$\nThis completes the first part of the problem.\n\nFor the second part, we must compute the numerical value for the mouse dose, $d_{\\mathrm{mouse}}$, using the supplied data:\n$d_{\\mathrm{human}} = 2.5$ $\\mathrm{mg/kg}$\n$W_{\\mathrm{human}} = 70$ $\\mathrm{kg}$\n$W_{\\mathrm{mouse}} = 0.020$ $\\mathrm{kg}$\n$\\beta = 0.75$\n\nFirst, we calculate the exponent $\\theta$:\n$$\n\\theta = \\beta - 1 = 0.75 - 1 = -0.25\n$$\nNow, we substitute the values into the derived scaling relation:\n$$\nd_{\\mathrm{mouse}} = d_{\\mathrm{human}} \\left(\\frac{W_{\\mathrm{mouse}}}{W_{\\mathrm{human}}}\\right)^{\\theta} = 2.5 \\left(\\frac{0.020}{70}\\right)^{-0.25}\n$$\nLet's evaluate the expression:\n$$\nd_{\\mathrm{mouse}} = 2.5 \\left(\\frac{2 \\times 10^{-2}}{7 \\times 10^1}\\right)^{-0.25} = 2.5 \\left(\\frac{1}{3500}\\right)^{-0.25}\n$$\nUsing the property $x^{-a} = \\frac{1}{x^a}$, we have $(1/3500)^{-0.25} = (3500)^{0.25}$.\n$$\nd_{\\mathrm{mouse}} = 2.5 \\times (3500)^{0.25}\n$$\nCalculating the numerical value:\n$$\n(3500)^{0.25} = (3500)^{1/4} \\approx 7.69160352\n$$\n$$\nd_{\\mathrm{mouse}} \\approx 2.5 \\times 7.69160352 \\approx 19.2290088\n$$\nThe problem requires the final answer to be rounded to four significant figures. Therefore, the mouse-equivalent dose is $19.23$ $\\mathrm{mg/kg}$.", "answer": "$$ \\boxed{19.23} $$", "id": "5039628"}, {"introduction": "During a PDX experiment, tumor growth is tracked by taking physical measurements, typically with calipers. These measurements are not perfect and are subject to experimental error. This exercise demonstrates how to quantify the uncertainty in your calculated tumor volume by propagating the errors from the primary length and width measurements, a crucial skill for understanding the reliability of your data and the statistical significance of your findings [@problem_id:5039651].", "problem": "A research team in Translational Medicine uses Patient-Derived Xenograft (PDX) models to evaluate antitumor efficacy. Tumor burden is assessed longitudinally with caliper measurements, where the longest dimension is recorded as length and the orthogonal shorter dimension as width. The laboratory employs the commonly used caliper-based estimator for tumor volume, given by the function $V(L,W) = \\frac{L\\,W^{2}}{2}$, where $L$ and $W$ are the true length and width, respectively, in $\\mathrm{mm}$, and $V$ is in $\\mathrm{mm}^{3}$. This estimator arises from approximating the tumor as a solid of revolution with geometry consistent with an ellipsoidal-like shape and is widely used for high-throughput assessments in small animal studies.\n\nIn a particular measurement session for one mouse, the experimenters recorded a mean length $L = 17.8$ $\\mathrm{mm}$ and a mean width $W = 9.6$ $\\mathrm{mm}$ from repeat caliper readings. Repeatability studies of the same operator and instrument under identical conditions indicate standard uncertainties (treated as standard deviations of approximately normally distributed, zero-mean measurement errors) of $s_{L} = 0.3$ $\\mathrm{mm}$ and $s_{W} = 0.2$ $\\mathrm{mm}$. Because the same caliper is zeroed once before both length and width readings, there is a non-zero correlation between the length and width errors; the correlation coefficient is $\\rho = 0.35$. Assume that the uncertainties are sufficiently small so that first-order (linear) uncertainty propagation is valid, and that $L$ and $W$ refer to the mean of several repeat readings so that $s_{L}$ and $s_{W}$ describe the standard uncertainties about those means.\n\nStarting from the general first-order multivariate uncertainty propagation based on a first-order Taylor expansion of $V(L,W)$ about the measured means and the covariance structure implied by $s_{L}$, $s_{W}$, and $\\rho$, compute the propagated standard uncertainty of the tumor volume, $s_{V}$, in $\\mathrm{mm}^{3}$. Express your final answer in $\\mathrm{mm}^{3}$ and round to four significant figures. Your answer must be a single real number.", "solution": "The problem statement is parsed and validated. It is found to be scientifically grounded, well-posed, objective, and complete. All provided data are consistent and physically plausible within the specified context of translational medicine and experimental measurement. It presents a standard, formalizable problem in error propagation. Therefore, I will proceed with the solution.\n\nThe problem requires the calculation of the propagated standard uncertainty for the tumor volume, $s_{V}$, given the estimator function $V(L,W) = \\frac{L\\,W^{2}}{2}$ and the uncertainties and correlation of the input measurements $L$ and $W$. The calculation will be based on a first-order Taylor series expansion of the function $V(L,W)$, which is the foundation of the general law of propagation of uncertainty.\n\nFor a general function $f$ of two correlated variables, $x$ and $y$, the variance of $f$, denoted $s_f^2$, is given by:\n$$\ns_f^2 \\approx \\left(\\frac{\\partial f}{\\partial x}\\right)^2 s_x^2 + \\left(\\frac{\\partial f}{\\partial y}\\right)^2 s_y^2 + 2 \\left(\\frac{\\partial f}{\\partial x}\\right)\\left(\\frac{\\partial f}{\\partial y}\\right) \\text{cov}(x,y)\n$$\nwhere $s_x$ and $s_y$ are the standard uncertainties (standard deviations) of $x$ and $y$, and $\\text{cov}(x,y)$ is their covariance. The partial derivatives are evaluated at the mean values of $x$ and $y$.\n\nThe covariance is related to the correlation coefficient $\\rho$ and the standard uncertainties by the definition $\\text{cov}(x,y) = \\rho s_x s_y$. Substituting this into the general formula gives:\n$$\ns_f^2 \\approx \\left(\\frac{\\partial f}{\\partial x}\\right)^2 s_x^2 + \\left(\\frac{\\partial f}{\\partial y}\\right)^2 s_y^2 + 2 \\rho s_x s_y \\left(\\frac{\\partial f}{\\partial x}\\right)\\left(\\frac{\\partial f}{\\partial y}\\right)\n$$\n\nIn our specific problem, the function is $V(L,W)$, and the variables are the tumor length $L$ and width $W$. The formula for the squared standard uncertainty of the volume, $s_V^2$, becomes:\n$$\ns_V^2 = \\left(\\frac{\\partial V}{\\partial L}\\right)^2 s_L^2 + \\left(\\frac{\\partial V}{\\partial W}\\right)^2 s_W^2 + 2 \\rho s_L s_W \\left(\\frac{\\partial V}{\\partial L}\\right)\\left(\\frac{\\partial V}{\\partial W}\\right)\n$$\n\nFirst, we must compute the partial derivatives of the volume function $V(L,W) = \\frac{L\\,W^{2}}{2}$ with respect to $L$ and $W$:\nThe partial derivative with respect to $L$ is:\n$$\n\\frac{\\partial V}{\\partial L} = \\frac{\\partial}{\\partial L}\\left(\\frac{1}{2} L W^2\\right) = \\frac{1}{2} W^2\n$$\nThe partial derivative with respect to $W$ is:\n$$\n\\frac{\\partial V}{\\partial W} = \\frac{\\partial}{\\partial W}\\left(\\frac{1}{2} L W^2\\right) = \\frac{1}{2} L (2W) = LW\n$$\n\nNext, we evaluate these partial derivatives at the given mean measured values: $L = 17.8 \\, \\mathrm{mm}$ and $W = 9.6 \\, \\mathrm{mm}$.\n$$\n\\frac{\\partial V}{\\partial L} = \\frac{1}{2} (9.6)^2 = \\frac{1}{2} (92.16) = 46.08 \\, \\mathrm{mm}^2\n$$\n$$\n\\frac{\\partial V}{\\partial W} = (17.8)(9.6) = 170.88 \\, \\mathrm{mm}^2\n$$\n\nThe given uncertainty parameters are:\nStandard uncertainty in length, $s_L = 0.3 \\, \\mathrm{mm}$.\nStandard uncertainty in width, $s_W = 0.2 \\, \\mathrm{mm}$.\nCorrelation coefficient, $\\rho = 0.35$.\n\nWe can now substitute all numerical values into the equation for $s_V^2$.\n$$\ns_V^2 = (46.08)^2 (0.3)^2 + (170.88)^2 (0.2)^2 + 2 (0.35) (0.3) (0.2) (46.08) (170.88)\n$$\nLet's compute each term separately.\n\nThe first term, related to the variance of length:\n$$\n\\left(\\frac{\\partial V}{\\partial L}\\right)^2 s_L^2 = (46.08)^2 (0.3)^2 = (2123.3664) (0.09) = 191.102976 \\, (\\mathrm{mm}^3)^2\n$$\n\nThe second term, related to the variance of width:\n$$\n\\left(\\frac{\\partial V}{\\partial W}\\right)^2 s_W^2 = (170.88)^2 (0.2)^2 = (29200.0144) (0.04) = 1168.000576 \\, (\\mathrm{mm}^3)^2\n$$\n\nThe third term, related to the covariance between length and width:\n$$\n2 \\rho s_L s_W \\left(\\frac{\\partial V}{\\partial L}\\right)\\left(\\frac{\\partial V}{\\partial W}\\right) = 2 (0.35) (0.3) (0.2) (46.08) (170.88)\n$$\n$$\n= (0.042) (7875.9168) = 330.7885056 \\, (\\mathrm{mm}^3)^2\n$$\n\nNow, we sum these three terms to find the total variance of the volume, $s_V^2$:\n$$\ns_V^2 = 191.102976 + 1168.000576 + 330.7885056 = 1689.8920576 \\, (\\mathrm{mm}^3)^2\n$$\n\nThe standard uncertainty of the volume, $s_V$, is the square root of the variance:\n$$\ns_V = \\sqrt{1689.8920576} \\approx 41.1083042 \\, \\mathrm{mm}^3\n$$\n\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures are $4$, $1$, $1$, and $0$. The fifth digit is $8$, so we round the fourth digit up.\n$$\ns_V \\approx 41.11 \\, \\mathrm{mm}^3\n$$\nThus, the propagated standard uncertainty of the tumor volume is $41.11 \\, \\mathrm{mm}^3$.", "answer": "$$\n\\boxed{41.11}\n$$", "id": "5039651"}, {"introduction": "Once tumor volume data has been collected, the central goal is to quantify the drug's efficacy. This practice focuses on calculating Tumor Growth Inhibition (TGI), the standard metric for assessing antitumor activity in PDX studies. You will learn why TGI is based on the *change* in tumor volume rather than absolute endpoint values, a critical distinction for correctly interpreting results, especially in realistic scenarios where experimental cohorts may not have perfectly matched baseline tumor sizes [@problem_id:5039689].", "problem": "In a translational medicine study using Patient-Derived Xenograft (PDX) models, a single patientâ€™s tumor was propagated into two cohorts of immunodeficient mice: a vehicle control cohort and a drug-treated cohort. Group-average tumor volumes were measured at baseline ($t=0$) and at a fixed endpoint time $t^{\\ast} = 21$ days. Let $V_{\\mathrm{control}}(t)$ and $V_{\\mathrm{treated}}(t)$ denote the cohort-average tumor volumes at time $t$ for control and treated groups, respectively. The recorded values are: $V_{\\mathrm{control}}(0)=105\\,\\mathrm{mm}^{3}$, $V_{\\mathrm{control}}(21)=315\\,\\mathrm{mm}^{3}$, $V_{\\mathrm{treated}}(0)=145\\,\\mathrm{mm}^{3}$, and $V_{\\mathrm{treated}}(21)=210\\,\\mathrm{mm}^{3}$. Using first principles appropriate to PDX efficacy assessment, derive the expression for Tumor Growth Inhibition (TGI) at $t^{\\ast}$ as a dimensionless measure that compares the drug-induced change in tumor volume to the change that would be observed in the absence of treatment, and then compute the TGI at $t^{\\ast}=21$ days from the provided data. Explain, based on your derivation, the correct interpretation of TGI when baseline volumes differ between cohorts, and why endpoint volumes alone are not an appropriate basis for comparison in such cases. Express the final TGI value as a decimal, rounded to four significant figures, with no percent sign.", "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It presents a standard scenario in preclinical oncology research using Patient-Derived Xenograft (PDX) models. The provided data are complete and consistent, and the task requires the derivation and application of a standard efficacy metric, Tumor Growth Inhibition (TGI). The problem is valid.\n\nThe core task is to derive a dimensionless measure for Tumor Growth Inhibition (TGI) that compares the effect of a drug treatment to a control condition. The problem specifies that this measure should compare the \"drug-induced change in tumor volume to the change that would be observed in the absence of treatment.\" This directive constitutes the first principle for our derivation.\n\nLet $V_{\\mathrm{control}}(t)$ and $V_{\\mathrm{treated}}(t)$ represent the average tumor volumes at time $t$ for the control and treated cohorts, respectively. The experiment is observed from a baseline time $t=0$ to an endpoint time $t^{\\ast}$.\n\nFirst, we define the change in tumor volume, or tumor growth, over the experimental period $[0, t^{\\ast}]$ for each cohort.\n\nThe change in volume for the control group is:\n$$ \\Delta V_{\\mathrm{control}} = V_{\\mathrm{control}}(t^{\\ast}) - V_{\\mathrm{control}}(0) $$\nThis quantity, $\\Delta V_{\\mathrm{control}}$, represents the natural growth of the tumor over the time period $t^{\\ast}$ in the absence of the therapeutic agent.\n\nThe change in volume for the treated group is:\n$$ \\Delta V_{\\mathrm{treated}} = V_{\\mathrm{treated}}(t^{\\ast}) - V_{\\mathrm{treated}}(0) $$\nThis quantity, $\\Delta V_{\\mathrm{treated}}$, represents the net growth of the tumor under the influence of the drug.\n\nThe \"inhibition\" of growth due to the drug is the difference between the growth that would have occurred (control growth) and the growth that was actually observed (treated growth). We can express this absolute growth inhibition as:\n$$ \\text{Absolute Growth Inhibition} = \\Delta V_{\\mathrm{control}} - \\Delta V_{\\mathrm{treated}} $$\nTo create a dimensionless, relative measure as required, we normalize this absolute inhibition by the growth that would have occurred without treatment, which is $\\Delta V_{\\mathrm{control}}$. This yields the standard formula for TGI:\n$$ \\text{TGI} = \\frac{\\Delta V_{\\mathrm{control}} - \\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} $$\nThis expression can be simplified to:\n$$ \\text{TGI} = 1 - \\frac{\\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} $$\nSubstituting the definitions for $\\Delta V_{\\mathrm{control}}$ and $\\Delta V_{\\mathrm{treated}}$, we arrive at the full expression for TGI based on the measured volumes:\n$$ \\text{TGI} = 1 - \\frac{V_{\\mathrm{treated}}(t^{\\ast}) - V_{\\mathrm{treated}}(0)}{V_{\\mathrm{control}}(t^{\\ast}) - V_{\\mathrm{control}}(0)} $$\nThis derived expression is the required dimensionless measure.\n\nThe problem asks for an explanation of the correct interpretation of TGI when baseline volumes differ. The derived formula shows that TGI is not based on the final tumor volumes $V(t^{\\ast})$ alone, but on the *change* in volumes, $\\Delta V$. This is critical. In a typical PDX experiment, even with careful staging, there will be variation in the initial tumor volumes ($V(0)$) between cohorts. If one were to compare only the endpoint volumes, for instance by calculating the ratio $V_{\\mathrm{treated}}(t^{\\ast}) / V_{\\mathrm{control}}(t^{\\ast})$, any pre-existing difference in baseline volumes would confound the interpretation of the drug's effect. For example, if the treated group started with significantly larger tumors, its final volume might still be larger than the control group's final volume, even if the drug were highly effective at slowing growth. This could lead to the erroneous conclusion that the drug is ineffective or even promotes growth. The TGI metric, by focusing on the net change $\\Delta V$, mathematically normalizes for differences in starting volumes. It correctly evaluates the treatment's effect on the *rate of growth* relative to the natural growth rate, which is the biologically and pharmacologically relevant question. Therefore, using endpoint volumes alone is not an appropriate basis for comparison when baseline volumes are unequal because it conflates the treatment effect with initial experimental conditions.\n\nNow, we compute the TGI at $t^{\\ast} = 21$ days using the provided data:\n$V_{\\mathrm{control}}(0) = 105\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{control}}(21) = 315\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{treated}}(0) = 145\\,\\mathrm{mm}^{3}$\n$V_{\\mathrm{treated}}(21) = 210\\,\\mathrm{mm}^{3}$\n\nFirst, we calculate the change in volume for each cohort.\nFor the control cohort:\n$$ \\Delta V_{\\mathrm{control}} = 315\\,\\mathrm{mm}^{3} - 105\\,\\mathrm{mm}^{3} = 210\\,\\mathrm{mm}^{3} $$\nFor the treated cohort:\n$$ \\Delta V_{\\mathrm{treated}} = 210\\,\\mathrm{mm}^{3} - 145\\,\\mathrm{mm}^{3} = 65\\,\\mathrm{mm}^{3} $$\nNow, we substitute these values into the TGI formula:\n$$ \\text{TGI} = 1 - \\frac{\\Delta V_{\\mathrm{treated}}}{\\Delta V_{\\mathrm{control}}} = 1 - \\frac{65}{210} $$\nThe ratio is:\n$$ \\frac{65}{210} \\approx 0.3095238... $$\nTherefore, the TGI is:\n$$ \\text{TGI} = 1 - 0.3095238... = 0.6904761... $$\nThe problem requires the final answer to be rounded to four significant figures.\n$$ \\text{TGI} \\approx 0.6905 $$\nThis value signifies that the treatment inhibited tumor growth by approximately $69.05\\%$ compared to the growth observed in the control group over the $21$-day period.", "answer": "$$\\boxed{0.6905}$$", "id": "5039689"}]}